Composition: Each uncoated tablet contains Metoclopramide Hydrochloride BP equivalent to anhydrous Metoclopramide Hydrochloride 10 mg.
Usage: Prescription anti-sickness medicine for selected indications.
Category: Antacid & Anti ulcer drugs
Therapeutic category: Antiemetic / Prokinetic
Manufacturer: Healthy Life Pharma Pvt. Ltd. (as supplied; WHO-GMP claim subject to verification)
Exporter: Healthy Inc (as supplied; Star Export House claim subject to verification)
SKU: Metoclopramide Tablets
Metoclopramide Tablets BP is listed for pharmaceutical business-to-business enquiries. Exact active ingredients, formulation, strength, pack configuration and manufacturer details should be confirmed against the product label and approved technical documentation before ordering.
Metoclopramide hydrochloride is a prescription antiemetic and gastrointestinal prokinetic. It is used for specific causes of nausea and vomiting and, in some jurisdictions, selected cases of diabetic gastroparesis or refractory gastroesophageal reflux. Approved indications and maximum treatment duration differ by country and formulation.
Healthy Life Pharma Pvt. Ltd. is named as manufacturer and Healthy Inc as exporter in the supplied product information. Claims concerning WHO-GMP certification, manufacturing facilities, export territories and capabilities require documentary verification.
| Product name | Metoclopramide Tablets |
|---|---|
| Brand supplied | Zerinorm |
| Composition | Each uncoated tablet contains Metoclopramide Hydrochloride BP equivalent to anhydrous Metoclopramide Hydrochloride 10 mg |
| Strength | 10 mg |
| Pharmacopoeial standard | BP (as supplied) |
| Dosage form | Uncoated oral tablet |
| Therapeutic class | Antiemetic / prokinetic / dopamine D2 receptor antagonist |
| Category | Antacid & Anti ulcer drugs (website category) |
| SKU | Metoclopramide Tablets |
| Packaging / shelf life | To be confirmed against approved label and stability records |
Manufacturing controls for immediate-release metoclopramide tablets may include qualified raw materials, validated blending and compression, content uniformity, disintegration, dissolution and suitable packaging. Light exposure and storage controls should follow formulation-specific stability studies. Specific lighting systems, equipment, pack formats or disintegration times are not established by the supplied label.
Release and stability testing should follow the applicable BP monograph and approved specifications, including identity, assay, uniformity of dosage units, dissolution and related substances as appropriate. Fixed numerical dissolution and assay limits should not be asserted without the relevant monograph and validated methods. Batch-specific certificates of analysis should be requested.
Metoclopramide blocks dopamine D2 receptors in pathways involved in nausea and vomiting and increases upper gastrointestinal motility. It may help gastric emptying in selected patients. Uses include certain nausea/vomiting indications and gastroparesis, subject to local approval; it is not a general treatment for all digestive complaints.
Important: The product is an antiemetic and prokinetic, not an antiprotozoal medicine. Chemotherapy-associated nausea usually requires protocol-specific antiemetic combinations; metoclopramide is not universally first-line.
Market registration may require manufacturing licenses, BP-compliant specifications, stability data, CTD/ACTD dossiers, certificate of analysis, GMP evidence, and country-specific authorization. Availability of FSC, COPP, dossiers, shipping options and approvals must be verified with the manufacturer/exporter before any claim or order.
What is Zerinorm? Zerinorm is the brand name provided for this metoclopramide hydrochloride BP 10 mg tablet.
Can it be used long term? Prolonged use increases the risk of tardive dyskinesia, which may be irreversible. In the US, use beyond 12 weeks is generally avoided except in rare cases; some other jurisdictions recommend much shorter courses for nausea and vomiting. Follow the local approved label.
Can it cause drowsiness? Yes. Drowsiness, restlessness and movement-related adverse effects can occur. Avoid driving until individual effects are known.
Is it an antiprotozoal? No; its relevant classification is antiemetic/prokinetic.
Dose, frequency and duration depend on the approved indication, patient age, kidney/liver function, interacting medicines and local labeling. A 10 mg tablet strength does not establish a universal dosing schedule or daily maximum. Dose reductions may be required with renal impairment. Use only as prescribed; do not extend treatment without medical review.
Boxed warning in US labeling: Metoclopramide can cause tardive dyskinesia, potentially irreversible involuntary movements; risk rises with duration and cumulative exposure. Other risks include acute dystonia, akathisia, parkinsonism, sedation, depression/suicidal thoughts, neuroleptic malignant syndrome and hyperprolactinemia. It is contraindicated in situations such as gastrointestinal obstruction/perforation, epilepsy, pheochromocytoma and history of tardive dyskinesia or dystonic reaction to metoclopramide, subject to local label. Review interactions with antipsychotics, other dopamine-blocking agents and medicines affecting serotonin. Seek prompt care for involuntary movements, severe muscle rigidity, high fever or serious mood changes.
Keep in original, appropriately protective packaging and store according to the approved product label. Protect from excessive heat, moisture and light where specified. Do not assume a 25°C limit or 36-month shelf life without verified product-specific stability data.